Abstract
Virus-based tumour vaccines offer many advantages compared to other antigen delivering systems. They generate concerted innate and adaptive immune response, and robust CD8+T cell responses. We engineered a non-replicating pseudotyped influenza virus (S-FLU) to deliver the well-known cancer testis antigen, NY-ESO-1 (S-NY-ESO-1 FLU). Intranasal or intramuscular immunization of NY-ESO-1 S-FLU virus in mice elicited a strong NY-ESO-1 specific CD8+T cell response in lungs and spleen that resulted in the regression of NY-ESO-1 expressing lung tumour and subcutaneous tumour respectively. Combined administration with anti PD-1 antibody, NY-ESO-1 S-FLU virus augmented the tumour protection by reducing the tumour metastasis. We propose that the antigen delivery through S-FLU is highly efficient in inducing antigen specific CD8+T cell response and protection against tumour development in combination with PD-1 blockade.
Competing Interest Statement
The authors have declared no competing interest.
Footnotes
Disclosure of Potential Conflicts of Interest: All authors report no potential conflicts of interest
Authors’ Contributions: MK, UG, AT and VC designed the study and MK, PR, TT, LL performed experiments. MK analysed the data and wrote the manuscript. MK, UG, PR, TT, LL, GP and AT edited the manuscript. All authors discussed the results, commented on the manuscript, and agreed on publication
